ARVN — ARVINAS, INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1655759 ·
Last close
$6.82
Market Cap
$446.61M
52W High
$14.51
52W Low
$6.33
ADV30
906,642
Next earnings
2026-11-03

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 500,000 400,000 -59,100,000 -53,900,000 607,500,000 88,000,000 93,700,000
Jun 2026 249,700,000 — 164,100,000 169,400,000 675,100,000 94,300,000 113,000,000
Mar 2026 15,600,000 — -63,800,000 -57,600,000 647,500,000 87,300,000 260,700,000
Dec 2025 9,500,000 — -74,600,000 -67,400,000 717,900,000 142,900,000 284,100,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-158,300,000
Investing CF
$218,600,000
Financing CF
$-73,300,000
CapEx
$-1,800,000
Dividends Paid
—
Buybacks
$-74,100,000
EPS Diluted TTM
$-0.24
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,554,500,000
Inventory
—
Receivables
$5,300,000
ST Investments
$470,400,000
EBIT TTM
$-33,400,000
Pretax Income TTM
$-8,800,000
Interest Exp TTM
—
Analysts
13

Yahoo Snapshot (yfinance, live)

Total Revenue
$275,300,000
EBITDA
$-25,100,000
Free Cash Flow
$-46,575,000
Enterprise Value
$-131,241,112
Total Cash
$558,400,000
Total Debt
$7,400,000
Shares Out
65,485,006
Trailing EPS
$-0.08
Book Value
$7.84
ROE
-1.8%
ROA
-2.4%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 262,600,000 -118,500,000 -80,800,000 717,900,000 284,100,000 433,800,000 -273,800,000
Dec 2024 263,400,000 -250,200,000 -198,900,000 1,091,400,000 529,800,000 561,600,000 -259,300,000
Dec 2023 78,500,000 -401,500,000 -367,300,000 1,304,600,000 644,600,000 660,000,000 -347,800,000
Dec 2022 131,400,000 -263,200,000 -282,500,000 1,268,800,000 703,900,000 564,900,000 -273,500,000

TTM Snapshot

Revenues TTM
$316,700,000
NetIncome TTM
$9,300,000
OpCashFlow TTM
—
Assets (Latest)
$675,100,000
Forward EPS
$-3.25

Max Pain — expiry 2028-01-21 (volume-derived — Yahoo OI feed degraded)

max pain strike: $7.00 · spot: $6.77 · call volume: 364 · put volume: 40
Expected Move to 2028-01-21: ±$3.73 (55.10%) — implied range $3.04 – $10.50 · ATM straddle on $7.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
PHAT Phathom Pharmaceuticals, Inc. $447.10M $5.50 —
EOLS Evolus, Inc. $442.80M $6.69 —
INDP Indaptus Therapeutics, Inc. $442.36M $3.32 —
DMAC DiaMedica Therapeutics Inc. $452.16M $8.38 —
EPRX EUPRAXIA PHARMACEUTICALS INC. $437.41M $6.62 —

News headlines (Yahoo Finance, 1h cache)

Arvinas to Present at Jefferies Global Healthcare Conference
2026-11-11 12:00 · Yahoo
Arvinas to Present Preliminary Clinical Data from Early Monotherapy Dose Escalation Cohorts in the Phase 1 Trial for ARV-393 (Zaloblideg), a PROTAC BCL6 Degrader, at the 2026 American Society of Hemat
2026-11-04 21:01 · Yahoo
What Arvinas Bears Saw Before The Fall
2026-11-04 08:11 · Yahoo
Arvinas, Inc. Q3 2026 Earnings Call Summary
2026-11-04 02:41 · Yahoo
Arvinas Inc (ARVN) (Q3 2026) Earnings Call Highlights: Cost Cuts, $558. ...
2026-11-04 01:04 · Yahoo
Arvinas (ARVN) Q3 2026 Earnings Call Transcript
2026-11-03 21:43 · Yahoo
What Arvinas (ARVN) Said on Its Q3 Earnings Call
2026-11-03 15:14 · Yahoo
Arvinas, Inc. (ARVN) Reports Q3 Loss, Misses Revenue Estimates
2026-11-03 12:40 · Yahoo
Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-03 12:00 · Yahoo
Arvinas Announces Return of Early Career Researcher Award to Recognize Innovation in Targeted Protein Degradation
2026-10-27 20:01 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.